Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
gptkb:capecitabine
gptkb:trastuzumab |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EH03
|
| gptkbp:brand |
gptkb:Tukysa
|
| gptkbp:CASNumber |
937263-43-9
|
| gptkbp:developer |
gptkb:Seattle_Genetics
|
| gptkbp:eliminationHalfLife |
8.5-17 hours
|
| gptkbp:hasMolecularFormula |
C26H24N8O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
tucatinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
HER2 inhibitor
|
| gptkbp:metabolism |
liver (CYP2C8, CYP3A4)
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
97.1%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:palmar-plantar_erythrodysesthesia
nausea vomiting diarrhea fatigue increased liver enzymes |
| gptkbp:usedFor |
gptkb:cancer
gptkb:HER2-positive_breast_cancer |
| gptkbp:bfsParent |
gptkb:Tukysa
|
| gptkbp:bfsLayer |
6
|